Browse the latest forensic toxicology articles or search the collection.
-
Does “Meth Mouth” Prove Chemical Damage From Smoking Methamphetamine?
Two analyses of a Los Angeles dental sample support a disease association while questioning a smoking-specific chemical explanation.
-
Did Methamphetamine Predict Worse Hemorrhage Outcomes—or Longer Hospital Stays?
Two retrospective intracerebral-hemorrhage cohorts separate hospital resource use from discharge disability, mortality and the risk of developing a stroke.
-
Does a Fivefold Psychosis Odds Ratio Establish a Prescription Amphetamine Safety Cutoff?
A 2024 case-control study found a dose association, but its 30-mg boundary used dextroamphetamine equivalents and did not establish absolute patient risk.
-
Methamphetamine and Aortic Dissection: Why a 60% Rat Result Is Not a Human Risk Estimate
A hospital-discharge association and a preconditioned rat experiment address different questions about amphetamines and aortic injury.
-
Does 97% Kidney Dysfunction Describe All Methamphetamine Users? Reading a Biopsy Cohort
A 112-patient biopsy series and a separate TMA case show why tissue diagnoses, selected denominators and drug causation need separate analysis.
-
Can Gastrointestinal Biopsy Findings Prove That Methamphetamine Caused Ischemia?
A 2025 case report combined urine toxicology, imaging and endoscopy. Its biopsy findings, H. pylori result and missing follow-up require careful separation from the proposed drug-related cause.
-
Does 47.2% Event-Free Survival Mean 47.2% Survival in Methamphetamine-Associated PAH?
A historical pulmonary arterial hypertension cohort used a composite endpoint. Death, transplantation and right-heart-failure hospitalization must remain distinct when interpreting its prognosis estimates.
-
Did N-Acetylcysteine Reduce Methamphetamine Use More Than Placebo in 153 Adults?
A historical randomized trial tested take-home oral NAC for 12 weeks. Improvements within both groups did not establish an added medication benefit.
-
Did Mirtazapine Reduce Methamphetamine Use Without Increasing Negative Oral-Fluid Tests?
A 2026 randomized trial found fewer self-reported methamphetamine-use days with mirtazapine. Its oral-fluid endpoint and adverse effects require separate interpretation.
-
Does Trace Methamphetamine in Amphetamine-Positive Urine Prove a Second Drug Was Taken?
A 2025 Swedish study found trace methamphetamine alongside amphetamine and investigated a possible minor metabolic pathway. Detection and proof of separate ingestion remain different questions.
-
Does Declining Mouse Activity Mean Methamphetamine Has Left the Brain?
A mouse experiment measured movement alongside blood and brain concentrations. Reduced movement, a null comparison and disappearance of drug are separate endpoints.
-
Can Oral Fluid Detect Amphetamine for Days After a Single Therapeutic Dose?
A controlled-dose study compared sensitive oral-fluid and urine testing. The resulting detection windows depend on the analyte, cutoff and model—not a universal clock.
-
Does a Methamphetamine Interaction Trial Show That Mirtazapine Protects the Heart?
A 15-person crossover trial tested a drug interaction, rather than cardiovascular protection. Its null interaction findings require careful interpretation.
-
Five Patients or Five Per Group? Reading Treatment-Resistant Methamphetamine Psychosis Evidence
A narrative review contrasts favorable case reports and a five-person open-label series with a ten-person comparison reporting no symptom-score difference. Study design determines what those findings can establish.
-
Did Better Avoidance Performance on Amphetamine Persist After Withdrawal? A Four-Rat Experiment
In a historical experiment, amphetamine increased responding in four selected rats and reduced shocks in three. The improved performance did not persist under saline conditions after abrupt or gradual withdrawal.
-
Do Receptor-Docking Scores Establish a Treatment for Methamphetamine Dependence?
A 2025 simulation study included methamphetamine in receptor-docking comparisons and proposed therapeutic possibilities for sartans. Predicted binding, receptor activity and clinical benefit remain separate evidentiary steps.
-
Do Ibudilast Findings in Methamphetamine Studies Prove a PDE4 Mechanism?
A 2016 review described methamphetamine-related behavioral effects of ibudilast and an analogue with negligible PDE inhibition. The comparison limits claims that PDE4 inhibition alone explains the findings.
-
Naloxone Was Documented but Usually Not Detected: What Eleven Living Cases Mean for Death-Investigation Interpretation
In an Orange County fentanyl study, naloxone administration was documented in eleven living-driver cases, but detected in only one blood specimen. The findings limit negative-result inferences without validating a postmortem naloxone detection rate.
-
Methadone and EDDP in Four Paired Vitreous–Blood Cases: Why the Table Matters More Than a Summary Ratio
Four original laboratory cases had lower vitreous methadone and EDDP than blood. Methadone vitreous/blood ratios calculated from the table ranged about 0.09–0.83, wider than the paper’s prose summary of 10–50%.
-
Vitreous 6-MAM in a Suspected Heroin Death: Drug Identification Was Different From Proving Overdose
One laboratory case reported vitreous 6-MAM of 42 ng/mL with morphine and codeine in blood and vitreous. The added heroin-metabolite finding supported exposure identification, but did not establish a universal fatal concentration or precise intake time.